Development of small molecule inhibitors/agonists targeting STING for disease

Biomedicine & Pharmacotherapy

Xiaoling Li¹  Mingyue Li²  Liao Cui³  Kaifeng Liu⁴  Yongqi Lan⁴  Lianxiang Luo⁵  Hui Luo⁵ 

[1] Animal Experiment Center of Guangdong Medical University, Zhanjiang, 524023, China;Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang, Guangdong, 524023, China;The First Clinical College, Guangdong Medical University, Zhanjiang 524023, China;The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, China;

关键词: Stimulator of interferon genes;    Disease;    Innate immune response;    Small molecule inhibitors;    Small molecule agonists;   

DOI  :  

来源: DOAJ

【 摘 要 】

Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) -stimulator of interferon genes (STING) signaling pathway is the primary immune response pathway in the cytoplasm. Pharmacological regulation of the STING pathway has good characteristics in both structure and function, which plays a significant role in the immunotherapy of autoimmune diseases, autoinflammatory diseases, and cancer. In this review, we summarized the activation of STING signaling pathway, the STING-related diseases, the development principle and the latest progress of inhibitors and agonists targeting STING. Our review demonstrates that STING signal pathway is a promising drug target, providing effective clues and correct guidance for the discovery of novel small molecule inhibitors/agonists that targeted STING for cancer, autoimmune, and inflammatory diseases.

【 授权许可】

Unknown